Avalyn Pharma Takes Its Inhaled Fibrosis Bet Public with Nasdaq IPO Filing

---

When the breath‑shortening reality of idiopathic pulmonary fibrosis (IPF) and its broader cousin, progressive pulmonary fibrosis (PPF), meets a nebulizer that can spray a drug directly into the alveoli, the chemistry feels almost cinematic. Avalyn Pharma, a clinical‑stage biopharma founded in 2019, believes that inhaled delivery can turn the tide for patients who today choke on the side‑effects of oral antifibrotics.

The company’s S‑1/A, filed with the SEC on April 29, 2026, spells out a clear‑cut story: raise money, finish Phase 2 trials, and sprint to a pivotal data set by 2027. The filing lists a modest offering of 2.5 million shares, underwritten by a syndicate that includes Morgan Stanley, UBS, Jefferies, Guggenheim and Evercore. No price range is disclosed, and the prospectus does not specify the exact proceeds target – a common omission in early‑stage biotech filings where the final pricing is still being calibrated.

The science behind the bet

Avalyn’s platform hinges on an exclusive license to PARI Technology Services’ eRapid® Nebulizer System with eFlow® technology. The device creates a fine aerosol that can deposit drug particles deep into the lung, theoretically achieving the same—or better—therapeutic exposure with a fraction of the systemic dose required by pills. The company’s pipeline is built around three wholly‑owned candidates:

• AP01 – inhaled pirfenidone – currently in a Phase 2b “MIST” trial for PPF. Early data are encouraging: more than four and a half years of open‑label extension (OLE) show near‑stabilization of forced vital capacity (FVC) at 48 weeks and >70 % of evaluated patients with HRCT‑based fibrosis stabilization or improvement.
• AP02 – inhaled nintedanib – in a Phase 2 “AURA” trial for IPF. The study is designed to confirm that the nebulized formulation can match or exceed the efficacy of the oral standard while trimming the gastrointestinal toxicity that drives discontinuation.
• AP03 – fixed‑dose inhaled combination of pirfenidone + nintedanib – slated to enter Phase 1 in late 2026, pending regulatory alignment. If successful, the combo could become the first dual‑antifibrotic inhaled therapy on the market.

The filing emphasizes that all three candidates will be pursued as combined drug‑device submissions to the FDA and foreign regulators, a strategy that could streamline approval but also adds a layer of complexity: the agency must evaluate both the pharmaceutical and the device in tandem.

Market opportunity and competitive edge

Pulmonary fibrosis remains a high‑mortality, low‑treatment‑options disease. In 2024, oral antifibrotics generated more than $4 billion in global sales, yet adherence is poor because of nausea, diarrhea and liver toxicity. PPF prevalence is roughly twice that of IPF, expanding the addressable patient pool.

Avalyn argues that its lung‑targeted delivery reduces systemic exposure, potentially improving tolerability and allowing higher local drug concentrations. The exclusive eRapid® platform gives the company a proprietary hardware advantage that competitors lack, and the team’s deep experience in rare respiratory disease and inhaled formulation science adds credibility.

How the money will be spent

The prospectus is deliberately vague on dollar‑by‑dollar allocations. Avalyn states that net proceeds, together with existing cash, cash equivalents and marketable securities, will fund the continued development of AP01 and AP02 and the pre‑clinical program for AP03. No specific percentages are disclosed, and the filing notes that actual use may differ substantially from the current intent.

What is clear is what won’t happen: the company does not anticipate paying cash dividends and plans to retain any future earnings to fuel growth. The lack of a detailed budget reflects the typical uncertainty of a biotech at this stage – the bulk of the cash will likely go to clinical trial costs, CRO fees, regulatory consulting, and scaling up manufacturing partnerships.

The risk gauntlet

The filing’s risk factors read like a checklist for any clinical‑stage biotech, but a few points stand out:

• Operating losses – Avalyn reported $85.2 million in 2025 and $49.7 million in 2024, with an accumulated deficit of $265.4 million. The company expects continued losses until (and possibly beyond) product commercialization.
• Regulatory uncertainty – The dual drug‑device pathway is untested for antifibrotics. FDA designations (Fast Track, Breakthrough, Priority Review, orphan‑drug) are discretionary and could be withdrawn.
• Execution experience – Avalyn has no demonstrated experience in later‑stage trials, commercial‑scale manufacturing, or sales and marketing. Success will require building those capabilities from scratch or partnering with outsized players.
• Third‑party reliance – The company outsources drug substance, product manufacturing, and the nebulizer device to contract manufacturers and relies on PARI for the device license. Supply‑chain disruptions or quality‑control lapses could stall development.
• Capital needs – The filing admits that substantial additional funding will be required. Failure to raise capital on acceptable terms could force program curtailment, dilution of existing shareholders, or even abandonment of the business.
• Intellectual‑property and licensing – Milestone, royalty and other payments under the PARI license could strain cash flow, especially if the company must pay them before any product revenue materializes.

These risks are amplified by macro‑economic headwinds – inflation, interest‑rate volatility, and geopolitical instability – that could affect the cost of capital and the ability to attract investors.

Why now?

Industry coverage notes that Avalyn recently closed a $100 million private round and that Bloomberg Law reports the company is targeting roughly $212 million in the IPO. The timing aligns with a broader resurgence in biotech IPO activity after a year‑long lull, and with the FDA’s recent willingness to grant accelerated pathways for rare‑disease therapies.

For investors, the offering is a classic high‑risk, high‑reward proposition: back a novel delivery technology that could unlock the full potential of existing antifibrotic drugs, or watch the company burn through cash without ever reaching a pivotal trial.

Bottom line

Avalyn Pharma’s S‑1/A paints a picture of a company at a crossroads. The clinical data for AP01 are promising, but the path to a market‑ready inhaled combo is littered with regulatory, manufacturing and financial obstacles. The 2.5 million‑share offering, led by a heavyweight underwriter syndicate, will provide the runway needed to finish Phase 2 studies and launch a Phase 1 for the combo candidate. Whether that runway translates into a breakthrough therapy – and a market‑changing IPO debut – will depend on the company’s ability to navigate the myriad risks laid out in its filing.

Investors should weigh the upside of a potentially differentiated therapy against the stark reality of deep‑pocketed losses, uncertain regulatory outcomes, and the need for further capital.

---

Key takeaways

1. Avalyn Pharma is developing inhaled versions of approved antifibrotic drugs, leveraging an exclusive eRapid® nebulizer platform to improve tolerability for IPF and PPF patients.
2. The S‑1/A proposes a 2.5 million‑share Nasdaq offering, underwritten by Morgan Stanley, UBS, Jefferies, Guggenheim and Evercore; price range and exact proceeds target are not disclosed.
3. Net proceeds will fund the continuation of Phase 2 trials for AP01 and AP02 and launch a Phase 1 for the combination candidate AP03, with no detailed allocation breakdown.
4. The filing highlights substantial operating losses, reliance on third‑party manufacturers, regulatory uncertainty for drug‑device combos, and the need for additional capital as primary risk factors.
5. Recent reports suggest the company may be aiming to raise around $212 million, positioning the IPO as a pivotal step toward pivotal trials slated for 2027.